Orphan drugs are forecast to remain one of the fastest growth areas of the global pharmaceutical market
According to Evaluate’s annual industry report, the “EvaluatePharma World Preview 2018, Outlook to 2024”, the rare disease space is predicted to capture 20% of the total $1.2trn market in 2024.
Evaluate provides commercial intelligence including product sales and consensus forecasts for commercial teams and their advisors within the global life science industry.
Supporting the growth of orphan drugs are the launches of novel therapies, including gene and cell therapies, as well as increased access to medicines globally.
Evaluate’s report also highlights factors that could act as a brake on industry growth, including the threat of biosimilarsfor some of the industry’s biggest products. The report shows $251bn of sales at risk between 2018 and 2024, teeing up a second patent cliff for the industry.
Additional findings from the report include:
Download the full report at www.evaluate.com/PharmaWorldPreview2018.